Ekso Bionics Holdings, Inc. · NASDAQ:EKSO
Ekso Bionics — Q2 2025 Earnings Presentation
19 slides from Ekso Bionics's earnings presentation, Jul 28, 2025
Slide 1: Investor Presentation
Improving health and quality of life with advanced robotics designed to enhance, amplify, and restore human function. Investor Presentation July 2025
Slide 2: Disclaimer
Disclaimer This presentation contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this presentation that do not describe historical facts may
Slide 3: Investment Highlights
Investment Highlights Ekso Bionics is a leading developer of exoskeleton solutions that augment human strength, endurance and mobility Stable legacy base business selling EksoNR and Ekso Indego Therapy to neuro-rehabilitation centers, inpatient and outpatient rehabilitation facilities, and VA medica
Slide 4: History
History Market Expansion and Reimbursement 2022 - Present Focus on driving operation excellence and scale. Acquire Indego from Parker Hannifin Dec 2022. CMS - April 11, 2024 – Reimbursement of $91K Ekso is NASDAQ Listed & Forges ahead in Neuro-Rehab 2016 - 2021 Ekso earns a reputation a respected na
Slide 5: “Life-Changing” Technology
“Life-Changing” Technology © 2024 Ekso Bionics, Inc 5
Slide 6: Innovative Wearable Robotics for Health and Daily Life
Innovative Wearable Robotics for Health and Daily Life Enterprise Personal Industrial Neuro-rehabilitation treatment via acute care, inpatient rehabilitation Overhead support in automotive, aerospace, hospitals (IRFs), outpatient rehab facilities, & VA medical centers Home and community use by indiv
Slide 7: Existing and Possible Future Indications for Use
Existing and Possible Future Indications for Use FDA 510(k) Cleared Indications for Use32 Spinal Cord Injury Stroke TBI Multiple Sclerosis Possible Future Indications • Parkinson’s (~8.5M 20.6m Global35 / ~305k US8 15m Global33 / 800k US15 69m Global34 / 2.8m US13 2.5m Global16 / ~1.0m US16 Global48
Slide 8: Expansive Market Growth Across the Care Continuum
Expansive Market Growth Across the Care Continuum Outpatient Post Acute Home ~$1B ~$1.9B ~$13.1B* THERAPY PERSONAL ENTERPRISE HEALTH ENTERPRISE HEALTH PERSONAL HEALTH - MOBILITY POST ACUTE NEURO-REHAB OUTPATIENT NEURO-REHAB Current reimbursement through VA and CMS 1,200 Inpatient Rehab Facilities (I
Slide 9: Enterprise Advancing Neuro-Rehab
Enterprise Advancing Neuro-Rehab Elevating the standard of care for Neurorehabilitation For Patients: Untethered environmental engagement promotes neuroplasticity and improved post-stroke outcomes27 Eliminates compensations while walking in the device, elevates precision in movement28 High rep
Slide 10: Expanding Global Customer Base
Expanding Global Customer Base 450+ centers, 900+ devices deployed worldwide Economic Value Proposition for EksoNR ATTRACT NEW PATIENTS • Novel technology attracts new patients 3 • Case Study37: After introduction of EksoNR, facility saw an 8% increase in volume of stroke patients @ ~$18,000 per pat
Slide 11: Personal Independence on the Go
Personal Independence on the Go Enabling Independence in the SCI community Continuity with Ekso Enterprise Health: • Individuals with SCI often rehab with Ekso products in Post-Acute Care creating continuity within healthcare systems as they transition to home Indego’s Competitive Advantage • Fastes
Slide 12: Reimbursement Established for Ekso Indego Personal
Reimbursement Established for Ekso Indego Personal CMS Rule Change CMS approved Ekso Indego Personal for lump sum reimbursement of $91K effective April 1, 2024. Market Size US SCI PATIENT • November 2023 – CMS finalized its Calendar Year 2024 Home Health INCIDENCE PREVALENCE POPULATION Prospective P
Slide 13: TAM in USA– Personal Mobility Exoskeletons
TAM in USA– Personal Mobility Exoskeletons General Debility Long Term Potential Future ~$34B FUTURE LONG-TERM POTENTIAL FOR GENERAL DEBILITY USAGE 1.5M Manual Wheelchair Users in USA (864K are 65 years or older)23 Neuro Degenerative Potential Future ~$13.1B TOTAL POTENTIAL ADDRESSABLE MARKET Include
Slide 14: Building a Scalable Go-to-Market Strategy
Building a Scalable Go-to-Market Strategy Efficient Market Access Through Partnerships LEVERAGE CLINICAL RELATIONSHIPS FOCUS ON HIGH VALUE ACTIVITIES • SCI patients rehab with neuro-rehabilitation centers • Keep operating cost low by leveraging partners • Ekso has a major presence in neuro-rehab cen
Slide 15: EVO – Industrial Exoskeleton & Occupational Health
EVO – Industrial Exoskeleton & Occupational Health Worker Challenges • In 2022, over 4.53m39 work-related injuries per year, accounting Upper Body Exoskeleton for 108m40 lost production days in the U.S. • Elevates and supports a worker’s shoulders • The second most common category of injuries is ove
Slide 16: Positioned for Future Growth
Positioned for Future Growth • A product portfolio offering a broad reach to a significantly larger addressable market while extending patient care through the continuum of care. • Significant growth potential through reimbursement programs beginning with CMS coverage for individuals living with an
Slide 17: Thank You
Thank You © 2024 Ekso Bionics, Inc 20
Slide 18: References
References 1. Centers for Medicare & Medicaid Services Regulation No. CMS-1781-F - Medicare Program; Inpatient Rehabilitation Facility Prospective Payment System for Federal Fiscal Year 2024 and Updates to the IRF Quality Reporting Program. 2. Centers for Medicare & Medicaid Services – Provider Data
Slide 19: References (cont.)
References (cont.) 23. Topics in Geriatric Rehabilitation Jan-Mar 2015, Philip S. Requejo, Ph.D., Evidence-Based Strategies for preserving Mobility for Elderly and Aging Manual Wheelchair Users 24. Wheelchair Foundation, Wheelchair Needs in the World (Additional Information) 25. Centers for Medicare
Ekso Bionics Holdings — Q2 2025 Earnings Presentation on 6ix